BriaCell Therapeutics Corp. Warrant expiring 2031 closed at $1.10 on Sep 28, up 3.29%, 14.0% below its highest close since Jan 14. Volume of 5.6K shares was 0.46× its 20-day average (below normal).
Split-adjusted performance: +18.3% over one month, +10.0% over six months.
Short interest was 4.0K shares at the Sep 15 settlement, up 61.1% from the prior report (1.0 days to cover).
What does BriaCell Therapeutics Corp. Warrant expiring 2031 do?
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer.
What sector is BCTXL in?
Healthcare, in the Pharmaceuticals industry.
About BriaCell Therapeutics Corp. Warrant expiring 2031
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
HQ: West Vancouver, A14 employeesListed Jan 14, 2026briacell.com
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
